Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines

Archives of Virology

Volumn 153, Issue 5, 2008, Pages 831-837

  Ghendon, Y ^a   Markushin, S ^a   Krivtsov, G ^a   Akopova, I ^a  

^a MECHNIKOV RESEARCH INSTITUTE FOR VACCINES AND SERA   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

CHITOSAN; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA VACCINE; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANIMAL; ANTIGENIC VARIATION; ARTICLE; BAGG ALBINO MOUSE; BIOSYNTHESIS; GENETICS; IMMUNOLOGY; INFLUENZA VIRUS A; MOUSE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; ANTIGENIC VARIATION; ANTIGENS, VIRAL; CHITOSAN; INFLUENZA A VIRUS; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; VACCINES, INACTIVATED;

AVES; AVIAN INFLUENZA VIRUS; HUMAN INFLUENZA VIRUS; MUS; ORTHOMYXOVIRIDAE;

EID: 42449152318     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-008-0047-4     Document Type: Article

References (20)

1. Belshe RB, Gruber WC, Mendelman PM, Cho I, Reisinger K, Block SL, Wittes J, Iacusio D, Piedra P, Treanor J, King I, Kotloff K, Bernstein DI, Hayden FG, Zangwill K, Yan L, Wollf M (2000) Efficacy of vaccination with live attenuated, cold adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 136:168-175
2. Couch R (2000) Influenza: prospects for control. Ann Intern Med 133:992-998
3. De Jong J, Beyer W, Palache A, Rimmelzwaan G, Osterhaus A (2000) Mismatch between the 1997/1998 influenza vaccine and the major epidemic A/H3N2 virus strain as the cause of an inadequate vaccine-induce antibody response to this strain in the elderly. J Med Virol 61:94-99
4. Felt O, Buri P, Curny R (1998) Chitosan, a unique polysaccharide for drug delivery. Drug Dev Ind Pharm 24:979-993
5. Gluck U, Gebbers J, Gluck R (1999) Phase 1 evaluation intranasal virosomal influenza vaccine with and without E. coli heat-labile toxin in adult volunteers. J Virol 73:7780-7786
6. Gross P, Hermogenes A, Sacks H, Lau J, Lewandowski R (1995) The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 123:518-527
7. Hehme N, Engelman H, Kuenzel W, Neumeier E, Saenger R (2004) Immunogenicity of a monovalent aluminium-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 103:163-171
8. Hirano S (1996) Chitin biotechnology application. Biotechnol Ann Rev 2:237-258
9. Illum L, Jabbal-Gill I, Hincheliffe A, Fisher A, Davis S (2001) Chitosan as a novel nasal delivery system for vaccines. Drug Deliv 51:81-96
10. Kendal A, Pereira M, Skehel J (1982) Concepts and procedures for laboratory-based influenza surveillance. WHO, Geneva
11. Mendelman PM, Rappaport R, Cho I, Block S, Gruber W, August M, Dawson D, Cordova J, Kemble G, Mahmood K, Palladino G, Lee MS, Razmpour A, Stoddard J, Forrest BF (2004) Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/2002-like H3N2 antigenic variant strain. Pediatr Infect Dis 23:1053-1055
12. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, Spyr C, Steffen R (2004) Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. New Engl J Med 350:896-903
13. Nicholson K, Tyrrel D, Harrison P, Plotter C, Jennings R, Clark A, Shild G, Wood J, Yetts R, Seagroat V, Huggins A, Anderson S (1979) Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions. J Biol Stand 7:123-136
14. Palache A (1997) Influenza vaccines: a reappraisal of their use. Drugs 54:841-856
15. Palache A (2006) International meetings on pandemic preparedness and control. Infl Bull ESWI 21:6-7
16. Podda A (2001) The adjuvanted influenza vaccine with novel adjuvants: experience with the MF 59-adjuvanted vaccine. Vaccine 19:2637-2680
17. Podda A, Del Guidice G (2003) MF 59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2:197-204
18. Potter C (1982) Inactivated influenza vaccine. In: Bear A (ed) Basic and applied influenza research. CRC Press, Boca Raton, pp 116-158
19. Smirnov Y, Lipatov A, van Beek R, Gitelman A, Osterhaus A, Claas E (2000) Characterization of a adaptation of an avian influenza A (H5N2) virus to a mammalian host. Acta Virol 41:1-8
20. Wood J, Williams M (1998) History of inactivated influenza vaccines. In: Nicholson K, Webster R, Hay A (eds) Textbook of influenza. Blackwell, London, pp 317-323